# Tolerance Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tolerance-bio

- Industry: Biotechnology
- Headquarters: Philadelphia, US
- Website: www.tolerancebio.com
- Total disclosed funding: $32M
- Latest round: Seed (Dec 19, 2024)
- Investors on record: 6

## About

Founded in 2023 and based in Pennsylvania, US, Tolerance Bio, Inc. operates as a biotechnology company that focuses on the enhancement of healthspan by targeting the thymus, an organ crucial for immune system function. In December 2024, Tolerance Bio, Inc. raised USD 20.2 million in seed funding led by returning investor Columbus Venture Partners, with participation from new investor Pacific 8 Ventures. Other returning investors Criteria Bio Ventures, Sessa Capital Management, BioAdvance, and Ben Franklin Technology Partners also participated in the round. The firm, as of December 2024, is led by its founder and CEO, Francisco Leon, and Scientific co-founder, Holger Russ.

Tolerance Bio specializes in developing therapies to restore and manipulate thymic function for treating immune-mediated diseases, including cancer, autoimmune disorders, transplant rejection, and infections. The company focuses on the thymus, a key organ for immune tolerance, and creates therapies to restore or preserve its function, improving immune health and longevity. Thymic dysfunction, which occurs with aging or certain medical treatments, contributes to immune-related diseases. Tolerance Bio's innovative, multi-platform approach includes stem cell-derived thymic epithelial cells, thymic organoids, and therapeutics designed to delay thymic involution, enhancing immune system function and reducing disease risk.

The company plans to utilize the December 2024 funding to advance its research and development of thymus-based therapies, including its allogeneic stem cell and pharmacological platforms, to treat immune-mediated diseases.

## Funding rounds

- Seed, Dec 19, 2024, $20M — Ben Franklin Technology Partners, BioAdvance, Sessa Capital, Columbus Venture Partners, Pacific 8 Ventures, Criteria Bio Ventures
- Seed, Oct 15, 2024, $12M — Ben Franklin Technology Partners, BioAdvance, Sessa Capital, Columbus Venture Partners, Criteria Bio Ventures

## Investors

- Ben Franklin Technology Partners (https://capitalatlas.ai/funds/ben-franklin-technology-partners) — Seed
- BioAdvance (https://capitalatlas.ai/funds/bioadvance) — Seed
- Sessa Capital — Seed
- Columbus Venture Partners (https://capitalatlas.ai/funds/columbus-venture-partners) — Seed
- Criteria Bio Ventures (https://capitalatlas.ai/funds/criteria-bio-ventures) — Seed
- Pacific 8 Ventures — Seed